Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study

Epithelioid sarcoma is a rare and aggressive soft-tissue sarcomo subtype. Over 90% of tumours have lost INI1 expression, leading to oncogenic dependen...